Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
NCT ID: NCT06039592
Last Updated: 2023-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
164 participants
OBSERVATIONAL
2022-04-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Can a modified drug therapy improve both left ventricular and mitral valve function in pediatric patients after mitral repair?
* Can the adverse drug reactions caused by the modified drug therapy be non-inferior (clinically acceptable) to those of the traditional drug therapy? Participants will be assigned to either the Modified Drug Therapy Group (comprising angiotensin-converting enzyme inhibitor (ACE-I), beta-blockers, diuretics, potassium supplements, and spironolactone) or the Traditional Drug Therapy Group (diuretics and potassium supplements) based on personal preferences and clinical assessments by their attending physicians. They will undergo a 6-months course of medication. Additionally, echocardiography, electrocardiograms, complete blood counts, biochemical tests, and measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) were conducted before the initiation of medication therapy and at 1 month, 3 months, and 6 months after treatment commencement. Researchers will compare the Modified Drug Therapy Group and the Traditional Drug Therapy Group to see if the recurrence rate of moderate to severe mitral valve regurgitation, as assessed by echocardiography after 6 months of treatment, is lower in the former than in the latter.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Drug Therapy for Pediatric Heart Failure
NCT06039540
Home Inotropic Therapy in Children
NCT00327899
Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation
NCT00113698
Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients
NCT00249067
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
NCT02010905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Modified Drug Therapy Group
Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/ mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).
Captopril Tablets
0.3mg/kg, tid
Metoprolol Oral Tablet
0.2mg/kg, bid
Spironolactone Tablets
2-4mg/kg, bid
Torsemide Tablets
0.2-0.5mg/mg, bid
Potassium citrate powder
0.06g/kg, tid
Traditional Drug Therapy Group
Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).
Torsemide Tablets
0.2-0.5mg/mg, bid
Potassium citrate powder
0.06g/kg, tid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Captopril Tablets
0.3mg/kg, tid
Metoprolol Oral Tablet
0.2mg/kg, bid
Spironolactone Tablets
2-4mg/kg, bid
Torsemide Tablets
0.2-0.5mg/mg, bid
Potassium citrate powder
0.06g/kg, tid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* after mitral valve repair
Exclusion Criteria
* Patients with severe pulmonary hypertension (pulmonary arterial pressure \>6 Wood·U)
* Patients with severe liver and kidney failure
* Patients who are allergic to related medications
* Patients with symptomatic hypotension who cannot tolerate related drugs
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Children's Medical Center
OTHER
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Guangzhou Women and Children's Medical Center
OTHER
Children's Hospital of Chongqing Medical University
OTHER
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shoujun Li
Director of Congenital Heart Surgery Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shoujun Li, MD
Role: STUDY_CHAIR
Chinese Academy of Medical Sciences, Fuwai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuwai hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-GSP-GG-19-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.